Kinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtual ESMO Targeted Anticancer Therapies Congress
07 mars 2022 06h00 HE
|
Kinnate Biopharma
Findings highlight the unmet medical need among cancer patients with BRAF Class II and Class III alterations who may not have access to approved targeted therapies SAN FRANCISCO and SAN DIEGO, March ...
Kinnate Biopharma Inc. to Participate in the 42nd Annual Cowen Health Care Conference
28 févr. 2022 16h05 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. Selected to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting
14 févr. 2022 08h00 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
07 févr. 2022 16h05 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium
19 janv. 2022 16h05 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248
18 janv. 2022 16h05 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. Provides Corporate Update and Highlights Key Upcoming 2022 Milestones
06 janv. 2022 16h05 HE
|
Kinnate Biopharma
Announces proof-of-concept preclinical data demonstrating activity of KIN-2787 in NRAS-mutant melanoma Provides update on ongoing KN-8701 trial with expansion to include patients with NRAS-mutant...
Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs at Upcoming Scientific Meetings
20 déc. 2021 16h05 HE
|
Kinnate Biopharma
AACR Special Conference: Targeting RAS presentation will highlight findings from real-world clinico-genomic study collaboration with Tempus investigating prevalence of Class II and Class III BRAF...
Kinnate Biopharma Inc. Announces Addition to NASDAQ Biotechnology Index
16 déc. 2021 16h05 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. Reports Third Quarter 2021 Financial Results
10 nov. 2021 16h05 HE
|
Kinnate Biopharma
In collaboration with Guardant Health, announced initial findings from BRAF Kinase Alteration Genomic Landscape and Real-World Clinical Outcomes Study Ended the quarter with cash, cash equivalents...